Current Studies

Contact: Dawn Brown, phone 520-742-1833
Email dbrown@neuroresearch.com

Northwest NeuroSpecialists Multiple Sclerosis Clinical Research Studies:

• Study 1
  Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)
  AKA: CombiRx Study
  
  Drug: Interferon beta 1-a/ glatiramer acetate/ placebo
  Sponsor Mount Sinai School of Medicine/ National Institute of Neurological Disorders and Stroke (NINDS)
  Phase III
  URL: http://ClinicalTrials.gov/show/NCT00211887



• Study 2
  Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
  
  Drug: Alemtuzumab/ interferon beta-1a (Rebif®)
  Sponsor Genzyme & Bayer Schering Pharma AG
  Phase III
  URL: http://ClinicalTrials.gov/show/NCT00530348



• Study 3
  Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
  
  Drug: Alemtuzumab/ interferon beta-1a (Rebif®)
  Sponsor Genzyme & Bayer Schering Pharma AG
  Phase III
  URL: http://ClinicalTrials.gov/show/NCT00548405



• Study 4
  Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
  
  Drug: CDP323 / placebo
  Sponsor UCB / Biogen Idec
  Phase II
  URL: http://ClinicalTrials.gov/show/NCT00484536



• Study 5
  Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ß-1a (Avonex®)
  AKA: the BRAVO Study
  
  Drug: Laquinimod / Interferon ß-1a (Avonex®) placebo
  Sponsor Teva Pharmaceuticals Industries
  Phase III
  URL: http://ClinicalTrials.gov/show/NCT00619476

For more information about these studies, please contact:
Joan Laguna, CCRC
Study Coordinator
Northwest NeuroSpecialists, PLLC
5860 N. La Cholla Blvd
Suite 100/Research
Tucson, AZ 85741-3537

Phone: 520-742-1833

Meet our research team

Experience

Recruitment

Current Studies

Patient Forms

Contact Research Site